The estimated Net Worth of Eschenbach Andrew C. Von is at least $617 Thousand dollars as of 5 August 2021. Andrew Von owns over 1,400 units of Bausch Health Companies Inc stock worth over $246,568 and over the last 12 years he sold BHC stock worth over $0. In addition, he makes $370,000 as Independent Director at Bausch Health Companies Inc.
Sign up
Andrew Eschenbach BHC stock SEC Form 4 insiders trading
Andrew has made over 3 trades of the Bausch Health Companies Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 1,400 units of BHC stock worth $36,316 on 5 August 2021.
The largest trade he's ever made was buying 3,000 units of Bausch Health Companies Inc stock on 12 August 2013 worth over $11,070. On average, Andrew trades about 458 units every 243 days since 2012. As of 5 August 2021 he still owns at least 38,647 units of Bausch Health Companies Inc stock.
You can see the complete history of Andrew Von stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Charles von Eschenbach biography
Dr. Andrew Charles von Eschenbach, M.D. is an Independent Director of the Company. Dr. von Eschenbach has been the President of Samaritan Health Initiatives, Inc., a health care policy consultancy, and an Adjunct Professor at University of Texas MD Anderson Cancer Center, since 2010. From 2005 to 2009, Dr. von Eschenbach served as Commissioner of the U.S. Food and Drug Administration (the “FDA”). He was appointed Commissioner of the FDA after serving for four years as Director of the National Cancer Institute at the National Institutes of Health. As a researcher, clinician and administrator, Dr. von Eschenbach served for twenty-six years at the University of Texas MD Anderson Cancer Center as Chairman of Urology, Director of the Prostate Cancer Research Program and Executive Vice President and Chief Academic Officer. He earned a B.S. from St. Joseph’s University and a medical degree from Georgetown University School of Medicine in Washington, D.C., where he completed a residency in surgery and urology and then a fellowship in urologic oncology. Dr. von Eschenbach has served as a director of private biotechnology companies Banyan Biomarkers, Inc. and Celularity, Inc. since 2012 and February 2018, respectively, and as a director of Wren Therapeutics, Ltd, a private biopharmaceutical company, since November 2019. Dr. von Eschenbach also been a member of the board of the Regan Udall Foundation of the FDA, a non-profit organization formed to advance regulatory science, since December 2018. From 2011 to 2013, Dr. von Eschenbach served as a director of BioTime, Inc., a clinical-stage biotechnology company, and as a director of Elan Corporation Plc, a pharmaceutical company which was acquired by Perrigo in 2013.
What is the salary of Andrew Eschenbach?
As the Independent Director of Bausch Health Companies Inc, the total compensation of Andrew Eschenbach at Bausch Health Companies Inc is $370,000. There are 18 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.
How old is Andrew Eschenbach?
Andrew Eschenbach is 78, he's been the Independent Director of Bausch Health Companies Inc since 2018. There are 1 older and 21 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.
What's Andrew Eschenbach's mailing address?
Eschenbach's mailing address filed with the SEC is C/O RADIUS HEALTH, INC., 22 BOSTON WHARF ROAD, 7TH FLOOR, BOSTON, MA, 02210.
Insiders trading at Bausch Health Companies Inc
Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas, and Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.
What does Bausch Health Companies Inc do?
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
What does Bausch Health Companies Inc's logo look like?
Complete history of Andrew Von stock trades at Radius Recycling and Bausch Health Companies Inc
Bausch Health Companies Inc executives and stock owners
Bausch Health Companies Inc executives and other stock owners filed with the SEC include:
-
Joseph Papa,
Chairman of the Board, Chief Executive Officer -
Paul Herendeen,
Chief Financial Officer, Executive Vice President -
Joseph C. Papa,
CEO & Chairman -
Thomas Appio,
President & Co-Head Bausch + Lomb/International -
William Humphries,
-
Christina Ackermann,
Executive Vice President, General Counsel -
Thomas J. Appio,
Pres & Co-Head Bausch + Lomb/International -
Paul S. Herendeen,
Exec. VP and Advisor to Chairman & CEO -
Joseph Gordon,
President & Co-Head Bausch + Lomb/International -
Christina M. Ackermann,
Exec. VP, Gen. Counsel & Head of Commercial Operations -
Thomas Ross,
Lead Independent Director -
Russel Robertson,
Independent Director -
Robert Power,
Independent Director -
Argeris Karabelas,
Independent Director -
Sarah Kavanagh,
Independent Director -
D. Robert Hale,
Independent Director -
Amy Wechsler,
Independent Director -
Richard De Schutter,
Independent Director -
Andrew Charles von Eschenbach,
Independent Director -
John Paulson,
Independent Director -
Tom G. Vadaketh,
Chief Financial Officer -
Frederick J. Munsch,
Controller & Chief Accounting Officer -
Kelly Webber,
Sr. VP & Chief HR Officer -
Stacey Williams,
VP of Marketing -
Michael McMyne,
VP of Sales -
Arthur J. Shannon,
Sr. VP and Head of Investor Relations & Communications -
Dr. Robert F. Butz,
VP of Medical & Scientific Affairs -
Osama A. Eldessouky,
CFO & Exec. VP -
Christian A Garcia,
Director -
Frank D. Lee,
Director -
Mark C. Mc Kenna,
President, Salix -
Holdings, L.P.Value Act Hol...,
-
Brett Icahn,
Director -
Steven D Miller,
Director -
Tom George Vadaketh,
EVP, Chief Financial Officer -
Holdings, L.P.Value Act Cap...,
-
Aimee J. Lenar,
EVP, US Pharma -
Seana Carson,
EVP, General Counsel -
David Robert Value Act Hold...,
-
Sam Eldessouky,
EVP & Chief Financial Officer -
Frederick Munsch,
SVP, Controller and CAO -
Robert Spurr,
President, U.S. Businesses -
Richard Mulligan,
Director -
John S Barresi,
SVP, Controller & CAO -
Jean Jacques Charhon,
EVP, CFO